Sun Pharmaceutical Industries Ltd - 524715 - Reg. 34 (1) Annual Report
Submission of Annual Report of the Company for the year ended March 31, 2021 along with the Notice of 29th Annual General Meeting of the Company06-08-2021
Sun Pharmaceutical Industries Ltd - 524715 - Reg. 34 (1) Annual Report
Submission of Annual Report of the Company for the year ended March 31, 2021 along with the Notice of 29th Annual General Meeting of the CompanySUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication
This is to inform you that a public notice by way of an advertisement has been published in all the editions (English Language) of the Financial Express dated August 5, 2021 and in Ahmedabad Edition (Gujarati Language) of the Financial Express dated August 5, 2021, regarding i) Notice of the 29th Annual General Meeting of the Company for the financial year 2020-21, to be held on Tuesday, August 31, 2021 by Video Conferencing/ Other Audio Visual means, ii) E-voting and iii) Book Closure. Pursuant to Regulation 30 read with Schedule III and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith copy of the advertisement published in the following newspapers: 1. Financial Express dated August 5, 2021 - Mumbai Edition (English Language) 2. Financial Express dated August 5, 2021 - Ahmedabad Edition (English Language) 3. Financial Express dated August 5, 2021 - Ahmedabad Edition (Gujarati Language)SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 03, 2021 for Raksha Sudhir ValiaBuy Welspun India: target of Rs 900: Sharekhan
Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 900 in its research report dated July 30, 2021.Sun Pharma: Ilumya illuminates
The specialty segment remains an important part of the Sun Pharma's strategy to scale up business and launch itself into the domain of complex molecules and novel dosage formsSun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Please find enclosed disclosure under Regulation 30 read with Schedule III of SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015, as amended ('Listing Regulations') read with Securities and Exchange Board of India circular no. CIR/CFD/CMD/4/2015 dated September 9, 2015 ('SEBI Circular').Top headlines: Sun Pharma's strong Q1 show, India-China military talks
Business Standard brings to you the top headlines on SaturdayEarnings Call for Q1FY22 of Sun Pharmaceutical Industries
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financial results for the first quarter ending June 30th, 2021.